window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Generative AI

  • Artificial Intelligence,Drug discovery,Partnerships & Funding

    Insilico Medicine signs $2.75bn AI drug discovery deal with Eli Lilly

    Insilico Medicine has signed a drug discovery collaboration with Eli [...]

    March 31, 2026
  • Artificial Intelligence,Biotech,Drug discovery,Oncology,Partnerships & Funding,Research & Development,Technology and platforms

    Evogene partners QUT on AI drug discovery for lung cancer resistance

    Evogene Ltd has partnered with Queensland University of Technology to [...]

    February 19, 2026
  • Artificial Intelligence,Biotech,Central Nervous System,Clinical Development,Drug Development,Immunology,Pharmaceuticals and therapeutics,Technology and platforms

    Insilico Medicine and CMS announce AI-powered drug discovery collaborations in CNS and autoimmune diseases

    Insilico Medicine and China Medical System Holdings Limited (CMS) have [...]

    February 15, 2026
  • Artificial Intelligence,Data Management,Market Access & Commercialization,Technology and platforms

    Veeva’s Sebastian Wurst on building the data foundation for enterprise AI

    The promise of AI in commercial biopharma is immense, with [...]

    November 7, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Rare Diseases

    Evogene and Tel Aviv University join forces to tackle metabolite aggregation in metabolic diseases

    Evogene Ltd. has announced a scientific collaboration with Professor Ehud [...]

    August 12, 2025
  • Artificial Intelligence,Clinical Development,Drug Development,Market Access & Commercialization,Research & Development,Technology and platforms

    Pharma’s AI tipping point: C-suite leaders move from pilots to enterprise scale

    The pharmaceutical sector is accelerating into an enterprise-scale AI future, [...]

    July 18, 2025
  • Artificial Intelligence,Clinical Development,Clinical Trials,Drug Development,Rare Diseases

    AI validation of rentosertib efficacy supports global trial expansion in IPF

    Qureight’s deep-learning biomarkers confirm representativeness of Insilico’s Phase 2a IPF [...]

    July 16, 2025
  • Artificial Intelligence,Technology and platforms,Women in Pharma

    AI governance in pharmacovigilance: Marie Flanagan calls for safety-specific frameworks to safeguard patient risk

    The integration of artificial intelligence into pharmacovigilance is prompting a [...]

    June 2, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Precision medicine,Technology and platforms

    Biostate AI raises $12M to build the ‘Netflix’ of molecular diagnostics using RNAseq and GenAI

    Biostate AI has raised $12 million in Series A funding [...]

    May 23, 2025
  • Artificial Intelligence,Drug Development

    FDA fast-tracks generative AI rollout following successful scientific review pilot

    The US Food and Drug Administration (FDA) has announced plans [...]

    May 14, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
  • European liver experts highlight rising MASLD burden at EASL symposium in Budapest
    Categories: Clinical studies, Gastroenterology, Healthcare leadership, Liver disease, Metabolic Diseases
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top